204707-42-6

Basic information

• Product Name: 4-FLUORO-2-METHOXYBENZOIC ACID METHYL ESTER
• Synonyms: 4-FLUORO-2-METHOXYBENZOIC ACID METHYL ESTER;METHYL 4-FLUORO-2-METHOXYBENZOATE;RARECHEM AL BF 1023;Methyl 4-fluoro-2-Methoxybenzoate, 97+%;Methyl 2-methoxy-4-fluorobenzoate;2-Fluoro-2-methoxybenzoic acid methyl ester
• CAS NO: 204707-42-6
• Molecular Formula: C₉H₉FO₃
• Molecular Weight: 184.16
• EINECS: 200-258-5
• Product Categories: Aromatic Esters;Acids & Esters;Anisoles, Alkyloxy Compounds & Phenylacetates;Fluorine Compounds
• Mol File: 204707-42-6.mol

Chemical Properties

• Melting Point: 134-136°C
• Boiling Point: 232℃
• Flash Point: 91℃
• Appearance: /
• Density: 1.184
• Vapor Pressure: 0.062mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-FLUORO-2-METHOXYBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-2-METHOXYBENZOIC ACID METHYL ESTER(204707-42-6)
• EPA Substance Registry System: 4-FLUORO-2-METHOXYBENZOIC ACID METHYL ESTER(204707-42-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 204707-42-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-fluoro-2-methoxybenzoic acid methyl ester is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to serve as a building block in the development of new medications, particularly those targeting specific biological pathways.
Used in Catalyst Applications:
In the field of chemistry, 4-fluoro-2-methoxybenzoic acid methyl ester is utilized as a catalyst to accelerate chemical reactions. Its ability to interact with other molecules and facilitate reaction rates makes it a valuable component in various chemical processes.
Used in Kinase Inhibitors:
4-fluoro-2-methoxybenzoic acid methyl ester is also employed in the development of kinase inhibitors, which are essential in the treatment of various diseases, including cancer. Kinase inhibitors work by blocking the activity of specific enzymes, thus disrupting the signaling pathways that promote cell growth and division.

InChI:InChI=1/C9H9FO3/c1-12-8-5-6(10)3-4-7(8)9(11)13-2/h3-5H,1-2H3

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 77-78-1 dimethyl sulfate 
• 392-04-1 methyl 4-fluoro-2-hydroxybenzoate 
• 74-88-4 methyl iodide 
• 865-33-8 potassium methanolate 
• 106614-28-2 methyl 2,4-difluorobenzoate 
• 865-34-9 lithium methanolate 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 395-82-4 4-fluoro-2-methoxy-benzoic acid 
• 606-45-1 2-methoxybenzoic acid methyl ester 

Downstream Products

• 151793-17-8 methyl 4-fluoro-2-methoxy-5-nitrobenzoate 
• 151793-18-9 methyl 5-amino-4-fluoro-2-methoxybenzoic acid 
• 151793-19-0 5-amino-4-fluoro-2-methoxybenzoic acid 
• 133849-95-3 5-Amino-N-(2-diethylamino-ethyl)-4-fluoro-2-methoxy-benzamide 
• 151793-16-7 5-Amino-N-[2-(cyclopropyl-methyl-amino)-ethyl]-4-fluoro-2-methoxy-benzamide 
• 314298-22-1 5-bromo-4-fluoro-2-methoxy-benzoic acid methyl ester 
• 157068-03-6 (4-fluoro-2-methoxyphenyl)methanol 
• 1108746-54-8 methyl 2-methoxy-4-(4-methylpiperazin-1-yl)benzoate 
• 1171824-17-1 methyl 4-fluoro-5-iodo-2-methoxybenzoate 
• 95420-77-2 2-methoxy-4-phenoxybenzoic acid 
• 788825-26-3 methyl 2-methoxy-4-phenoxybenzoate 
• 1154414-87-5 tert-butyl 4-(3-methoxy-4-methoxycarbonylphenyl)piperazine-1-carboxylate 

Relevant articles and documents

Fluorinations of unsymmetrical diaryliodonium salts containing: Ortho -sidearms; Influence of sidearm on selectivity

Activated aromatics were reacted with two different fluoroidoane reagents 1 and 2 in the presence of triflic acid to prepare only the para-substituted diaryliodonium salts. With fluoroiodane 1 the unsymmetrical diaryliodonium salts contained an ortho-propan-2-ol sidearm, whereas the alcohol sidearm was eliminated to form an ortho-styrene sidearm in the reaction with fluoroiodane 2. Only the diaryliodonium salts containing a styrene sidearm were fluorinated successfully to deliver para-fluorinated aromatics in good yields.

Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1

We previously disclosed the discovery of rationally designed N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1 (GlyT-1), represented by analogues 10 and 11. We describe herein further structure-activit

Pyrazolo [3,4 - the b] pyridine and [...] composition preparation method and use of (by machine translation)

The present invention provides a pyrazolo [3,4 - the b] pyridine and [...] compound of preparation and use, in particular, the present invention provides a following formula (I) compounds are shown, wherein the definition of each group as described in the specification. The compounds of the invention has excellent tyrosine kinase inhibiting activity, so can be used for preparing a series of treating diseases associated with the tyrosine kinase activity of the drug. (by machine translation)

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein

Ortho-selectivity in SNAr substitutions of 2,4-dihaloaromatic compounds. Reactions with anionic nucleophiles

The nucleophilic addition of organic anions to aromatic compounds with halogens positioned both ortho and para to activating groups was studied in a variety of solvents. Substrates showed strong preferences for ortho substitution in most cases. Evidence is presented for activating group-dependent coordination, which contributes to very high ortho-selectivity in nonpolar solvents. This also drives the overall reaction rate in these solvents, and is of close to the same magnitude of rate increase derived from polar solvents. para-Products are maximized by using crown ethers in protic solvents. Solvent effects overall are very different from corresponding reactions with amine nucleophiles due primarily to the different charges present in the transition states, and to solvation of the nucleophile.

Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols

In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzen

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.